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ABSTRACT
Background: Protein intake in early infancy has been suggested to
be an important risk factor for later obesity, but information on
potential mechanisms is very limited.
Objective: This study examined the influence of protein intake in
infancy on serum amino acids, insulin, and the insulin-like growth
factor I (IGF-I) axis and its possible relation to growth in the first
2 y of life.
Design: In a multicenter European study, 1138 healthy, formula-fed
infants were randomly assigned to receive cow-milk–based infant
and follow-on formulas with lower protein (LP; 1.77 and 2.2 g
protein/100 kcal) or higher protein (HP; 2.9 and 4.4 g protein/100
kcal) contents for the first year. Biochemical variables were mea-
sured at age 6 mo in 339 infants receiving LP formula and 333
infants receiving HP formula and in 237 breastfed infants.
Results: Essential amino acids, especially branched-chain amino
acids, IGF-I, and urinary C-peptide:creatinine ratio, were signifi-
cantly (P , 0.001) higher in the HP group than in the LP group,
whereas IGF–binding protein (IGF-BP) 2 was lower and IGF-BP3
did not differ significantly. The median IGF-I total serum concen-
tration was 48.4 ng/mL (25th, 75th percentile: 27.2, 81.8 ng/mL) in
the HP group and 34.7 ng/mL (17.7, 57.5 ng/mL) in the LP group;
the urine C-peptide:creatinine ratios were 140.6 ng/mg (80.0,
203.8 ng/mg) and 107.3 ng/mg (65.2, 194.7 ng/mg), respectively.
Most essential amino acids, IGF-I, C-peptide, and urea increased
significantly in both the LP and HP groups compared with the
breastfed group. Total IGF-I was significantly associated with
growth until 6 mo but not thereafter.
Conclusions: HP intake stimulates the IGF-I axis and insulin release
in infancy. IGF-I enhances growth during the first 6 mo of life. This
trial was registered at clinicaltrials.gov as NCT00338689. Am J
Clin Nutr 2011;94(suppl):1776S–84S.
INTRODUCTION
A high milk protein intake with infant formula provided during
the first year of life was shown to induce excessive weight gain in
early childhood in a double-blind, randomized controlled trial (1).
Animal and observational studies in humans, as well as some small
controlled trials in infants (2–4), showed diet, and especially
protein intake, to modulate blood concentrations of insulin-like
growth factor (IGF)-I (5). The IGF axis is known to regulate early
growth and was also shown to influence adipose tissue differen-
tiation and early adipogenesis in animals and in humans (6–8).
IGF-I may exert effects in adipose tissue in an autocrine–paracrine
and an endocrine way. It shows a strong structural homology to
insulin, which is also reflected in the binding motifs of the IGF
binding proteins, which suggests a role of IGF-I and its binding
proteins in glucose homeostasis. Furthermore, amino acids, and
in particular the branched-chained amino acids (BCAAs) leu-
cine, isoleucine, and valine, are physiologic stimulators of insulin
secretion (9).
Because of the different quality of cow-milk protein, formula-
fed infants have higher protein intakes than breastfed infants (10).
They are reported to have higher concentrations of many plasma
amino acids (11) and higher IGF-I concentrations (12, 13), along
with different growth patterns in the first 2 y of life (14, 15).
Therefore, the hypothesis was raised that the higher protein in
formula causes higher BCAA, IGF-I, and insulin concentrations
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and thereby leads to accelerated growth, increased adipose tissue,
and increased risk of later obesity (16, 17). We explored the effects
of protein intake on biochemical and endocrine markers at the age
of 6 mo in healthy term infants who participated in the European
Childhood Obesity Project (1). Furthermore, we looked into the
effect of IGF-I and C-peptide on growth during the first 2 y of life.
During this period we have seen a differential growth between the
higher and lower protein groups in the same study (1).
SUBJECTS AND METHODS
Inclusion criteria and dietary intervention
The subjects were participants of a double-blind, randomized,
multicentric intervention trial conducted in Germany, Belgium,
Italy, Poland, and Spain. The formula-fed infants were randomly
assigned to receive formulas with higher and lower protein
content, which were given to the children until 12 mo of life. In
addition, a nonrandomized reference group of breastfed infants
was followed (1). Briefly, eligible for study participation were
apparently healthy, singleton, term infants who were born from
uncomplicated, singleton pregnancies. Infants were enrolled
during the first 8 wk of life (median age at study entry: 14 d).
Formula-fed infants had to be exclusively formula fed at the end
of the eighth week of life. Breastfed children had to be exclu-
sively breastfed for the first 3 mo.
Infant formulas were replaced by follow-on formulas from the
fifth month of age onwards, as has been suggested by the Eu-
ropean Union Directive of 1991 (18). The lower protein (LP) and
higher protein (HP) infant and follow-on formulas (manufactured
by Bledina, Steenvoorde, France, and provided free of charge to
families) differed in the content of cow-milk protein but had an
identical energy density because the difference in protein content
was adjusted through the fat content (Table 1). The composition
of all study formulas complied with the 1991 European Union
Directive on Infant and Follow-on Formulae (18), and protein
contents represented approximately the lowest and highest
amounts, respectively, of the range accepted in this Directive.
The relative contents of amino acids did not differ between all
4 formulas (eg, BCAAs made up’23% of the protein content in
all infant and follow-on formulas). An exception was the LP
infant formula, which was supplemented with small amounts of
arginine and tryptophan.
Recruitment procedures in all centers were designed to pro-
mote and support breastfeeding. Introduction of any food other
than study formula or breast milk before the age of 4 completed
months was discouraged, but no other attempts were made to
influence the local and family traditions of the introduction of
solids into the infants’ diets.
TABLE 1
Macronutrient and amino acid content of study formulas compared with human milk1
Infant formula Follow-on formula
Human milkLower Higher Lower Higher
Whey:casein ratio 1:4 1:4 1:4 1:4 3:2
Energy (g/100 mL) 69.9 69.8 72.7 72.5 70
Proteins (g/100 mL) 1.25 2.05 1.6 3.2 1.2
Protein (% of energy) 7.1 11.7 8.8 17.6 —
Nonprotein nitrogen (g/100 mL) 0.07 0.1 0.08 0.15 —
Nonprotein nitrogen (% of energy) 0.4 0.6 0.45 0.9 —
Lipids (g/100 mL) 3.9 3.5 4.0 3.27 3.6
Carbohydrates (g/100 mL) 7.5 7.5 7.6 7.6 7.4
Essential amino acids (dL/100 mL)
Cysteine + methionine 40 66 52 103 37
Histidine 32 53 41 82 25
Isoleucine 77 128 100 200 57
Leucine 119 197 154 308 104
Lysine 94 155 121 243 69
Phenylalanine 58 97 75 151 39
Threonine 56 92 72 144 46
Tryptophan 22 29 23 46 19
Valine 84 139 108 216 58
Total essential amino acids 582 956 746 1493 432
Nonessential amino acids (dL/100 mL)
Alanine 42 69 54 108 37
Arginine 50 74 57 115 38
Asparagine 89 147 115 230 83
Glutamic acid 286 473 369 738 179
Glycine 24 40 31 62 23
Proline 135 223 174 348 88
Serine 71 118 92 184 45
Tyrosine 62 103 80 161 43
Total nonessential amino acids 759 1247 972 1946 536
1 Human milk values were taken from the Davis Area Research on Lactation, Infant Nutrition, and Growth (DARLING) study (19); amino acid
concentrations in human milk were taken from reference 20.
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The study followed the recommendations made in the CONSORT
(Consolidated Standards of Reporting Trials) guidelines (21). It
was approved by the ethics committees of all study centers, and
written informed parental consent was obtained for each infant.
Study population
The allocation, demographic, dietary, anthropometric, and
clinical characteristics of all 1678 originally enrolled infants has
been described in detail previously (1). A total of 1200 children
were still participating in the study at the age of 6 mo. In all 312
children from Italy, no blood was collected. In 812 (91%) of the
remaining 888 children, blood or urine samples were available
[606 children in the intervention groups and 206 in the breastfed
group (Figure 1)]. For 588 children, both blood and urine
samples were collected at the age of 6 completed months.
Breastfed infants, as well as girls, abstained significantly more
often from blood or urine testing than formula-fed infants or
boys, respectively. There were also some differences between
countries in the frequency of blood or urine sampling: whereas
all the Polish children’s samples were available, only 78% of the
Belgium children’s samples were available. The characteristics
of the population of the LP and HP groups with blood and/or
urine samples did not differ significantly from the original 1678
children or between both groups at 6 mo of age with regard to
gender, mother’s education, smoking in the family, mother’s
age, and birth weight, which indicates that the randomization
was not substantially disturbed in this subsample.
The intakes of energy and protein as measured by 3-d food
protocols, and their difference between the HP group and the LP
group, were approximately the same in our subsample as in the
whole study group (1), showing the same energy intake in both
groups except at 6 mo (when the LP group had slightly higher
intakes), and higher protein intakes up to age 12 mo in the HP
group. Weight and length were measured in accordance with
standardized procedures at baseline (ie, inclusion in the study)
and at 6, 12, and 24mo. Anthropometric measures were expressed
as z scores relative to the growth standards of the World Health
Organization for breastfed children (22).
Laboratory procedures
At 6 mo of age, a venous blood sample was drawn and a urine
sample was collected with the use of a baby urine collection bag.
Efforts were undertaken to draw blood 2 h after the last feed.
Urine and serum samples were stored at 270C and transported
on dry ice to one central laboratory (The Children’s Memorial
Health Institute, Warsaw, Poland) for analysis of serum amino
acids, total IGF-I, free IGF-I, IGF-BP2, IGF-BP3, and urinary
C-peptide and creatinine. Glucose and urea were analyzed in the
respective laboratories of the local study centers.
Quantitative amino acids analysis was performed by HPLC
with the use of the Pico-Tag method (Waters, Milford, MA). The
samples were deproteinized by ultra filtration (Ultrafree; Milli-
pore, Billerica, MA). Precolumn derivatization of the amino acids
with phenylisothiocyanate was followed by separation of the
derivatized amino acids by reversed HPLC. Amino acids were
detected by measurement of the absorbance of the column eluate
at 254 nm. The computer program Millenium 32 (Waters) was
used for the identification of amino acids and the calculation of
the results (23).
The variables of the IGF axis were measured with the use of
immunoradiometric assay kits, and urinary C-peptide with a ra-
dioimmunoassay kit (all from Diagnostic Systems Laboratories
Inc, Webster, TX). Urine creatinine was analyzed with a kinetic
assay based on the Jaffe reaction in an automated ADVIA 1650/
Mega (Bayer Healthcare AG, Leverkusen, Germany). The urine
samples were centrifuged at 2000 · g for 10 min at 4C before
measurement. Urinary C-peptide was expressed per mg urinary
creatinine/dL, as suggested by others (24, 25).
Amino acids, variables of the IGF axis, and C-peptide were not
normally distributed and are presented as median values with
interquartile ranges (25th and 75th percentile). Group compar-
isons were done with a Kruskal-Wallis rank test as appropriate.
FIGURE 1. Numbers of participants and of samples available for analysis at 6 mo of age.
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Spearman rank correlations with Bonferroni correction for
multiple testing were calculated to look for correlations between
weight-for-length at baseline and at 6 and 12 mo of age, the
difference between consecutive time points, and IGF-I total and
C-peptide. Significance was assumed at P , 0.05. All statistical
analyses were performed with Stata 9.2 (StataCorp, College
Station, TX).
RESULTS
Serum amino acids and urea
The comparison of serum concentrations of the 18 amino acids
assessed is summarized in Table 2. The totals of these free
amino acids were 2841 (interquartile range: 2523, 3186) lmol/L
in the LP and 3041 (interquartile range: 2679, 3394) lmol/L in
the HP group (P , 0.001). The biggest differences between the
LP group and the HP group were seen for the BCAAs valine
(+42%), leucine (+37%), and isoleucine (+32%). Concentrations
for all other essential amino acids were 10% higher in the HP
group than in the LP group, and the sum of all essential amino
acids was significantly higher (P , 0.001) in the HP group than
in the LP group (Figure 2). In contrast, most nonessential amino
acids were either not different or even lower in the HP group;
only tyrosine and asparagine were significantly higher in the HP
group. Total nonessential amino acids had lower concentrations
in the HP group (P = 0.001). We observed no differences in
amino acid concentrations between males and females in both
formula groups. Serum urea concentration was significantly
higher in infants fed HP formula (Table 3).
IGF-I, IGF-BP2, and IGF-BP3
In the HP formula group, serum concentrations of total IGF-I
and free IGF-I were ’40% higher than in the LP formula group,
whereas IGF-BP2 concentrations were ’30% lower (Table 3).
There was no significant group difference for IGF-BP3.
Urinary C-peptide and serum glucose
Infants receiving the HP formula showed a higher urinary C-
peptide concentration and C-peptide:creatinine ratio and a lower
serum glucose concentration than did those receiving the LP
formula (Table 3).
IGF-I total, C-peptide, and anthropometric data at baseline
and at 6, 12, and 24 mo
Total IGF-I was positively associated with weight-for-length at
6, 12, and 24 mo (Figure 3). However, looking at change in
weight-for-length between baseline and 6 mo, 6 and 12 mo, and
12 and 24 mo, only the first was significantly associated with
total IGF-I concentrations (Figure 3). This association persisted
after adjustment for the baseline measurement of weight-for-
length. C-peptide showed no association with weight-for-length
or change in weight-for-length (data not shown).
Breastfed children
There were remarkable differences between both formula
groups and the breast milk group. Compared with the breastfed
group, variables of the IGF axis and C-peptide were increased in
the formula groups. Total IGF-I, free IGF-I, and IGF-BP3 con-
centrations were all significantly,  ’60%, lower in the breastfed
TABLE 2
Serum amino acid (AA) concentrations in infants at 6 mo of age fed higher-protein (HP) or lower-protein (LP) formula
and in breastfed (BF) infants1
LP HP
P value
(HP compared with LP) BF
Essential amino acids (lmol/L)
Isoleucine 64 (50, 80)2 85 (62, 114)3 ,0.001 58 (46, 74)
Leucine 120 (98, 143)4 165 (124, 212)3 ,0.001 106 (90, 133)
Lysine 166 (134, 197)3 197 (156, 248)3 ,0.001 145 (121, 184)
Methionine 31 (26, 39)3 35 (26, 46)3 ,0.001 27 (22, 35)
Phenylalanine 72 (61, 83)3 84 (70, 100)3 ,0.001 61 (48, 74)
Threonine 126 (101, 154) 142 (118, 173)3 ,0.001 119 (92, 150)
Tryptophan 56 (47, 67)4 67 (54, 82)3 ,0.001 60 (50, 74)
Valine 214 (182, 247)3 304 (241, 376)3 ,0.001 172 (143, 208)
Nonessential amino acids (lmol/L)
Alanine 440 (346, 526) 420 (349, 517) 0.304 430 (355, 495)
Arginine 115 (97, 137) 110 (91, 128) 0.038 113 (91, 129)
Asparagine 54 (45, 64) 58 (47, 68)4 0.015 52 (45, 64)
Aspartic acid 25 (17, 35) 27 (19, 35) 0.143 26 (18, 38)
Glutamine 605 (542, 683)3 556 (490, 613)3 ,0.001 664 (573, 748)
Glutamic acid 122 (95, 168) 115 (88, 172) 0.179 130 (90, 193)
Glycine 267 (217, 319)3 230 (199, 273)2 ,0.001 220 (185, 264)
Histidine 105 (88, 123)3 107 (93, 124)3 0.215 88 (74, 105)
Serine 161 (138, 194)3 159 (140, 189)3 0.750 187 (156, 207)
Tyrosine 83 (70, 103)3 101 (76, 125)3 ,0.001 66 (54, 80)
1 All values are medians; interquartile ranges in parentheses. P values were computed with the use of the Kruskal-
Wallis rank test.
2–4 Significantly different from the BF group: 2P , 0.05, 3P , 0.001,4P , 0.01.
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than in the formula groups (Table 2). IGF-BP2 was markedly
higher in the breastfed group than in both formula groups. Serum
glucose, urinary C-peptide, and the C-peptide:creatinine ratio
were all significantly lower in the breastfed than in the formula
groups (Table 2). Essential amino acids, especially BCAAs, were
lower in the breastfed group than in the LP group, whereas
nonessential amino acids had approximately the same concen-
trations (Figure 2).
DISCUSSION
This randomized controlled trial shows that the endocrine and
metabolic response of infants is significantly affected by dietary
protein supply. HP compared with LP formula increased plasma
concentrations of essential amino acids, especially BCAAs,
whereas nonessential amino acids were lowered. Higher protein
intakes increased concentrations of total and free IGF-I, whereas
IGF-BP2 was decreased and IGF-BP3 was unaffected by the
protein intake; urinary C-peptide concentrations, which repre-
sented endogenous insulin secretion, increased and serum glu-
cose concentrations decreased. Breastfed children had generally
lower plasma amino acid concentrations and a less active IGF-1
axis and lower insulin production than did formula-fed children.
Lowering the protein intake with infant formula resulted in
a metabolic and endocrine response in formula-fed infants more
similar to that of breastfed infants. In addition, we have shown
that IGF-I concentrations at 6 mo of age are associated with
weight gain in the first 6 mo of life, but not thereafter.
Serum amino acids
Changes in plasma concentrations of amino acids due to nu-
tritional intake, and their significance, have not been studied ex-
tensively (26). Therefore, most conclusions from observations in
this study can only be speculative. Whereas the HP group had
a 50% higher protein supply than did the LP group, with
identical amino acid composition, total serum free amino acids
were only marginally higher in the HP group. The serum amino
acid pattern was significantly shifted toward essential amino
FIGURE 2. Serum amino acid concentrations in formula-fed and breastfed infants at 6 mo of age.
TABLE 3
Serum concentrations of insulin-like growth factor (IGF)-I free, IGF-I total, IGF–binding protein (IGF-BP) 2, IGF-BP3,
glucose, urea, and urinary C-peptide in infants receiving lower-protein (LP) and higher-protein (HP) formula and in
breastfed (BF) infants1
Variable LP HP
P value (HP
compared with LP) BF
IGF-I free (ng/mL) 0.43 (0.27, 20.77) 0.60 (0.34, 1.11) ,0.001 0.31 (0.21, 0.48)
IGF-I total (ng/mL) 34.7 (17.7, 57.5) 48.4 (27.2, 81.8) ,0.001 14.1 (5.1, 33.2)
IGF-BP2 (ng/mL) 1090 (865, 1438) 765 (575,1013) ,0.001 1370 (1055, 1740)
IGF-BP3 (ng/mL) 2908 (2449, 3440) 2969 (2538, 3483) 0.248 2454 (1984, 2794)
C-peptide:creatinine (ng/mg) 107.3 (65.2, 194.7) 140.6 (80.0, 203.8) 0.030 57.0 (27.3, 119.3)
C-peptide (ng/mL) 19.5 (9.4, 34.6) 26.9 (13.3, 45.6) 0.002 9.3 (3.5, 20.1)
Glucose (mg/dL) 85 (77, 93) 83 (77, 89) 0.022 86 (79, 93)
Urea (mg/dL) 18 (14, 21) 29 (20, 36) ,0.001 11 (8, 16)
1 All values are medians; interquartile ranges in parentheses. P values were computed with the use of the Kruskal-
Wallis rank test. P , 0.001 for comparison of LP and BF groups (except for glucose). P , 0.001 for comparison of HP and
BF groups.
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acids, an effect that was also seen in other small randomized trials
that compared a higher and lower protein intake with infant for-
mula (2, 27). Another study (28) that compared groups with
higher and lower protein intake showed at 3 mo of age a differ-
ence in plasma concentrations of leucine, isoleucine, tyrosine,
phenylalanine, lysine, and threonine but not for histidine, methi-
onine, cysteine, tryptophan, or valine. In agreement with our re-
sults, the same authors observed that even a formula with 1.1
g/100-mL protein content did not produce amino acid concen-
trations similar to those of breastfed children, which emphasizes
that not only the amount of protein but also the type of protein,
for instance the whey-to-casein ratio, and corresponding dif-
ferences in amino acid composition, are of importance (29).
Formula-fed infants tend to have higher postprandial (27) and
fasting (28, 39, 31) concentrations of BCAAs compared with
breastfed infants. The strong effect of protein intake on BCAAs
seen in this study may be important for biological and functional
effects. The lower concentrations of nonessential amino acids
with higher protein are not fully understood but may be related to
the extensive catabolism of absorbed nonessential amino acids in
the intestine, as well as the major contribution of their de novo
synthesis on serum concentrations. Nonessential amino acids are
more extensively catabolized in the intestine than are essential
amino acids (32) and thus are less affected by an increased protein
intake.
Like other authors (30), we interpret the significant differences
in plasma urea concentrations between the HP group and the LP
group as well as between both formula groups and the breastfed
group as a reflection of enhanced amino acid catabolism. However,
when formula-fed and breastfed infants are compared, several
FIGURE 3. Insulin-like growth factor I (IGF1) total at 6 mo of age and weight-for-length (WFL) at baseline (median 14 d) and at 3, 6, and 12 mo, as well as
difference in WFL between 0 and 6 mo and 6 and 12 mo with number of children, Spearman correlation coefficient, and P value.
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other studies did not find differences (28, 33, 34), which highlights
the limitation of this comparison because formula differs in many
aspects (eg, composition and kinetics of digestion).
Insulin and IGF axis
The increased urinary C-peptide:creatinine ratio is a reflection
of enhanced insulin secretion. Higher urinary C-peptide concen-
trations and postprandial insulin secretion were reported pre-
viously in formula-fed compared with breastfed or between LP and
HP formula–fed children (35–38).
The observed effect of formula protein contents on total and free
IGF-I agrees with earlier observations of lower IGF-I concen-
trations in breastfed compared with formula-fed infants (12, 13,
39) as well as observations of higher concentrations of IGF-I
associated with higher protein or milk intakes in infants and
children (40–42), adolescents (39), and adults (43–45). Several
animal and human studies have reported reduced IGF-I concen-
trations caused by underweight or protein-caloric malnutrition
(46). Amino acid supply seems to play an important role in the
insulin-relatedmetabolic activity. BCAAs, especially leucine, have
been reported to stimulate insulin release (47, 48) but not nec-
essarily IGF-I (49).
The observed lower IGF-BP2 concentrations agree with the
increased IGF-I total and free concentrations, which indicates
a marked modulation of the IGF axis by higher dietary protein
intake (5). IGF-BP2 acts mainly by reduction of the IGF-I
bioavailability and was shown to inhibit adipogenesis by mod-
ulation of IGF-I activity (50). Overexpression of IGF-BP2 in
a transgenic mouse model led to a significant reduction in fat cell
size in both chow-fed and high-fat-fed mice, which further
supports an important function of IGF-BP2 in adipocyte biology
and a protective role IGF-BP2 against obesity development (51).
Contrary to IGF-I and IGF-BP2, the concentrations of IGF-
BP3 did not differ between the formula-fed groups. This is
somewhat surprising because IGF-BP3 is the major binding
protein of IGF-I, and binds .90% of IGF-I (52). However, IGF-
BP3 is relatively stable and is only depressed after prolonged
periods of severe malnutrition (5). Factors other than protein
intake have to explain the difference in IGF-BP3 between for-
mula-fed and breastfed infants. Some experimental data suggest
an inhibitory effect of IGF-BP3 on adipogenesis (53). IGF-BP3
has also been shown to inhibit insulin action independently of
IGF-I and was reported to induce insulin resistance (51).
Long-term effects of elevated IGF-I concentrations in infancy
have been proposed. Formula feeding, higher protein intake, and
higher IGF-I concentrations in infancy have been associated with
lower IGF-I concentrations in later life (39, 54–56), whereas
breastfeeding is associated with lower IGF-I in infancy but higher
IGF-I in later childhood (54). In otherwise healthy adults, a lower
IGF-I concentration is associated with an increased risk of both
ischemic heart disease and diabetes (57) as well as with neoplasia
of the prostate and the breast (58). Therefore, early programming
of the IGF-I axis may have a relevant effect on the later risk of
adult diseases (54).
IGF-I, C-peptide, and growth
In the present study, IGF-I at 6 mo of age was associated with
weight at 6, 12, and 24 mo but with weight gain only in the first
6 mo of age and not thereafter. This might indicate that IGF-I
concentrations are especially important in early growth. IGF-I
has been shown to be positively related to fetal growth and birth
weight (59–61). Savino et al (62) also showed that IGF-I was
directly correlated with the weight, body mass index, and tri-
cipital skinfold thickness during the first 5 mo of age. Whereas
one study showed that IGF-I was associated with immediate
postnatal growth (63), another study, which looked at IGF-I
concentrations at 3 mo of age and later growth, showed an as-
sociation only with length gain until 12 mo of age but not with
weight gain (64). Our observation agrees with our previous
observation (1) that higher protein intake led to a differential
weight gain during this period with a persistent weight-for-length
difference until 24 mo of age.
Strengths and limitations
A strength of this study is the double-blind randomized design
and the large number of infants included, which provides con-
vincing evidence for a causal relation between the dietary in-
tervention and the observed metabolic and endocrine response. In
contrast to some previous studies that evaluated the effects of
formula feeding on plasma amino acid patterns, in our study only
the total protein content, but not the amino acid composition, of the
study formulas was modified, which is of importance because
some plasma amino acid concentrations were shown to be higher
when whey-dominant rather than casein-dominant protein sources
were supplied (29). A limitation of the study was that, to limit the
burden of the healthy infants who participated, only blood samples
from one time point were available. The chosen time point of 6mo,
however, is considered to bewithin the relevant timewindowwhen
diet may affect growth, body composition, and long-term health.
Therewas considerable attrition but we did not have any indication
of a differential drop-out between intervention groups, or of
a relevant introduction of bias.
Potential relevance
Our results indicate that protein intake of infants modulates the
IGF axis and insulin release, which is associated with a higher
weight-for-length and body mass index at the age of 2 y (1).
These effects have all been shown to influence later health. A
reduced protein content of formulas, more similar to the protein
content of human milk, supports an endocrine and metabolic
profile of formula-fed infants that is closer to that of breastfed
infants. However, considerable differences between formula-fed
and breastfed infants remain that are not explained by the level of
protein supply.
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